Payer Renegotiations And Hospice Demand Will Support A Fairly Valued Outlook

Catalysts

About Enhabit

Enhabit provides home health and hospice care services across the United States.

What are the underlying business or industry changes driving this perspective?

• Although payer renegotiations have recently produced higher per visit rates with some national contracts, the reliance on periodic multi year renewals and exposure to future reimbursement pressure from both Medicare and Medicare Advantage could limit pricing power and put a ceiling on revenue growth and margins over time.
• While hospice census and revenues in the latest quarter are tied to growing demand for end of life care, length of stay is relatively flat around 100 days and management highlights holiday related volatility, which could constrain further operating leverage and earnings expansion if referral timing becomes less favorable.
• Although the visits per episode program in Home Health has reduced average visits per episode from roughly 15 to about 13 in pilot branches, a full rollout across more than 90 additional branches and the need to fund 10 new support resources may compress savings at scale and limit the benefit to segment margins and consolidated EBITDA.
• While de novo hospice locations have reached profitability with Q3 revenue of US$0.8 million and EBITDA of US$0.3 million, continued de novo expansion to hit the 10 location goal for 2025 requires upfront investment that could weigh on free cash flow and delay any further step up in net margins.
• Despite recent debt reduction of about US$100 million since Q4 2023 and lower annualized cash interest expense of roughly US$19 million, the remaining leverage at 3.9x net debt to adjusted EBITDA leaves the company sensitive to any slowdown in adjusted EBITDA growth, which could limit future flexibility for M&A and temper earnings growth.

Assumptions

This narrative explores a more pessimistic perspective on Enhabit compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming Enhabit's revenue will grow by 5.8% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from -1.1% today to 1.8% in 3 years time.
• The bearish analysts expect earnings to reach $22.1 million (and earnings per share of $0.42) by about January 2029, up from $-11.9 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 24.4x on those 2029 earnings, up from -39.3x today. This future PE is greater than the current PE for the US Healthcare industry at 23.3x.
• The bearish analysts expect the number of shares outstanding to grow by 0.25% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.61%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Continued growth in hospice admissions and census, supported by seven consecutive quarters of sequential hospice census increases and 12.6% year over year hospice census growth in Q3 2025, could support higher long term revenue and segment earnings than implied by a flat share price view, especially as hospice adjusted EBITDA margin reached 27.3% of segment revenue.
• Ongoing payer contract renegotiations that have already delivered a low double digit per visit rate increase with one national payer and an additional contract update effective November 2025 could gradually lift average reimbursement rates, supporting revenue and potentially net margins over time.
• Expansion of the hospice de novo program, with all 2024 de novos already profitable and contributing US$0.8 million of revenue and US$0.3 million of EBITDA in Q3 2025, alongside the plan to reach 10 new locations in 2025, may extend Enhabit’s footprint and add incremental revenue and EBITDA above what a flat share price would imply.
• Company wide efforts to optimize visits per episode in Home Health, which have already reduced total visits per episode to 13.4 in Q3 2025 compared with the prior year, and the planned rollout to nearly all branches with added authorization and virtual clinical resources, could structurally lower unit costs and support higher consolidated EBITDA margins.
• Use of consistent free cash flow to reduce bank debt by US$100 million since Q4 2023, bringing net debt to adjusted EBITDA leverage down to 3.9x and lowering annualized cash interest expense by about US$19 million, may strengthen the balance sheet and free up more cash for reinvestment, which can support earnings and potentially shift market sentiment away from a flat share price outcome.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Enhabit is $8.5, which represents up to two standard deviations below the consensus price target of $9.75. This valuation is based on what can be assumed as the expectations of Enhabit's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $12.0, and the most bearish reporting a price target of just $8.5.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $1.2 billion, earnings will come to $22.1 million, and it would be trading on a PE ratio of 24.4x, assuming you use a discount rate of 7.6%.
  
• Given the current share price of $9.23, the analyst price target of $8.5 is 8.6% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.